Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity

Liver International

Volumn 37, Issue 7, 2017, Pages 1065-1073

  Pavlides, Michael ^a,b,c   Banerjee, Rajarshi ^d   Tunnicliffe, Elizabeth M ^a   Kelly, Catherine ^d   Collier, Jane ^b   Wang, Lai Mun ^e   Fleming, Kenneth A ^e   Cobbold, Jeremy F ^b,c   Robson, Matthew D ^a   Neubauer, Stefan ^a,c   Barnes, Eleanor ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^d Oxford University Hospitals ^*  (United Kingdom)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

diagnostic accuracy; non alcoholic steatohepatitis; non invasive test; sensitivity and specificity

Indexed keywords

ADULT; AREA UNDER THE CURVE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; ELASTOGRAPH; FATTY LIVER; FEMALE; HEPATITIS; HEPATOGRAPHY; HUMAN; LIVER BALLOONING; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SCANNER; PERCUTANEOUS BIOPSY; PILOT STUDY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; AGED; ALGORITHM; BIOPSY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; ELASTOGRAPHY; EVALUATION STUDY; LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; BIOPSY; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 85019975163     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13284     Document Type: Article

References (29)

1. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–415.
2. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131.
3. Hyysalo J, Mannisto VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014;60:839–846.
4. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 2015;148:547–555.
5. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.
6. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–121.
7. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–654. e1-9; quiz e39-40.
8. Rawlins SR, Mullen CM, Simon HM, et al. Wedge and needle liver biopsies show discordant histopathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Gastroenterol Rep (Oxf) 2013;1:51–57.
9. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014;39:254–269.
10. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167–174.
11. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713.
12. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–835.
13. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862–1871.
14. Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60:1920–1928.
15. Cui J, Heba E, Hernandez C, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology. 2016;63:453–461.
16. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016;150:626–637. e7.
17. Loomba R, Cui J, Wolfson T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol. 2016;111:986–994.
18. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014;60:69–77.
19. Piechnik SK, Ferreira VM, Dall'armellina E, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010;12:69.
20. Tunnicliffe EM, Banerjee R, Pavlides M, Neubauer S, Robson MD. A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 (shMOLLI-T1) in the liver. J Magn Reson Imaging 2017;45:450–462.
21. Pavlides M, Banerjee R, Sellwood J, et al. Multi-parametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2016;64:308–315.
22. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575.
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.
24. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentaenoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377–384. e1.
25. Heye T, Yang SR, Bock M, et al. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012;22:1224–1232.
26. Haimerl M, Verloh N, Fellner C, et al. MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score. Sci Rep 2014;4:5621.
27. Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol 2014;24:959–966.
28. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457.
29. Wyatt J, Hubscher S, Bellamy C. Tissue Pathways for liver biopsies for the investigation of medical disease and for focal lesions. London, UK: Royal College of Pathologists; 2014.